554 related articles for article (PubMed ID: 29635163)
41. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
Topp MS; Gökbuget N; Zugmaier G; Klappers P; Stelljes M; Neumann S; Viardot A; Marks R; Diedrich H; Faul C; Reichle A; Horst HA; Brüggemann M; Wessiepe D; Holland C; Alekar S; Mergen N; Einsele H; Hoelzer D; Bargou RC
J Clin Oncol; 2014 Dec; 32(36):4134-40. PubMed ID: 25385737
[TBL] [Abstract][Full Text] [Related]
42. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis.
Yu J; Wang W; Huang H
Hematology; 2019 Dec; 24(1):199-207. PubMed ID: 30479190
[TBL] [Abstract][Full Text] [Related]
44. Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies.
Poussin M; Sereno A; Wu X; Huang F; Manro J; Cao S; Carpenito C; Glasebrook A; Powell DJ; Demarest S
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253637
[TBL] [Abstract][Full Text] [Related]
45. Development of a minimal physiologically-based pharmacokinetic/pharmacodynamic model to characterize target cell depletion and cytokine release for T cell-redirecting bispecific agents in humans.
Jiang X; Chen X; Jaiprasart P; Carpenter TJ; Zhou R; Wang W
Eur J Pharm Sci; 2020 Apr; 146():105260. PubMed ID: 32058058
[TBL] [Abstract][Full Text] [Related]
46. Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting.
Li X; Zhang P; Sun H; Han L; Jiang Z; Yu J
Expert Opin Biol Ther; 2023; 23(12):1193-1195. PubMed ID: 37852928
[TBL] [Abstract][Full Text] [Related]
47. Targeting T cells to tumor cells using bispecific antibodies.
Frankel SR; Baeuerle PA
Curr Opin Chem Biol; 2013 Jun; 17(3):385-92. PubMed ID: 23623807
[TBL] [Abstract][Full Text] [Related]
48. Cytokine release syndrome: Who is at risk and how to treat.
Frey N
Best Pract Res Clin Haematol; 2017 Dec; 30(4):336-340. PubMed ID: 29156206
[TBL] [Abstract][Full Text] [Related]
49. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab.
Wilke AC; Gökbuget N
Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327
[TBL] [Abstract][Full Text] [Related]
50. Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy.
Yang Y; Yang Z; Yang Y
Front Immunol; 2021; 12():686031. PubMed ID: 34305918
[TBL] [Abstract][Full Text] [Related]
51. Clinical Experience with Bispecific T Cell Engagers.
Gökbuget N
Recent Results Cancer Res; 2020; 214():71-91. PubMed ID: 31473849
[TBL] [Abstract][Full Text] [Related]
52. Overcoming leukemia heterogeneity by combining T cell engaging bispecific antibodies.
Hoseini SS; Espinosa-Cotton M; Guo HF; Cheung NV
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239418
[TBL] [Abstract][Full Text] [Related]
53. CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas.
Watkins MP; Bartlett NL
Expert Opin Investig Drugs; 2018 Jul; 27(7):601-611. PubMed ID: 29940805
[TBL] [Abstract][Full Text] [Related]
54. Blinatumomab: a historical perspective.
Nagorsen D; Kufer P; Baeuerle PA; Bargou R
Pharmacol Ther; 2012 Dec; 136(3):334-42. PubMed ID: 22940266
[TBL] [Abstract][Full Text] [Related]
55. Supportive care measures for bispecific T-cell engager therapies in haematological malignancies.
Chen LY; Kothari J
Curr Opin Support Palliat Care; 2024 Jun; 18(2):92-99. PubMed ID: 38652455
[TBL] [Abstract][Full Text] [Related]
56. CD33 directed bispecific antibodies in acute myeloid leukemia.
Clark MC; Stein A
Best Pract Res Clin Haematol; 2020 Dec; 33(4):101224. PubMed ID: 33279180
[TBL] [Abstract][Full Text] [Related]
57. Epratuzumab and Blinatumomab as Therapeutic Antibodies for Treatment of Pediatric Acute Lymphoblastic Leukemia: Current Status and Future Perspectives.
Franca R; Favretto D; Granzotto M; Decorti G; Rabusin M; Stocco G
Curr Med Chem; 2017; 24(11):1050-1065. PubMed ID: 28088906
[TBL] [Abstract][Full Text] [Related]
58. Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.
Bumma N; Papadantonakis N; Advani AS
Future Oncol; 2015; 11(12):1729-39. PubMed ID: 26075441
[TBL] [Abstract][Full Text] [Related]
59. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
[TBL] [Abstract][Full Text] [Related]
60. Bispecific Antibodies: A Review of Development, Clinical Efficacy and Toxicity in B-Cell Lymphomas.
Salvaris R; Ong J; Gregory GP
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33946635
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
